Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

Scientific and Technical Support Services

Active

Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract seeks professional scientific and technical support services to assist the Department of Homeland Security’s Science and Technology Directorate in executing a broad spectrum of operations and programmatic initiatives, including research, development, testing, and evaluation. The services required must be delivered by individuals with strong scientific backgrounds and operational expertise to ensure effective technical oversight and program success across high-priority DHS missions. Performance of the work is expected to occur in Washington, District of Columbia, with no geographic restrictions beyond this primary location. The solicitation is classified under NAICS code 541714 for Scientific Research and Development Services and is not set aside for any specific small business category, meaning all eligible entities may compete. The point of contact for technical inquiries is Cora Newton, reachable via phone or email, while Geoff Seay serves as the Small Business Specialist for matters related to small business participation. No solicitation number or posted date is provided, indicating this is a forecast notice rather than an active solicitation, serving as an advance indicator of future procurement intent.

General Info

Professional scientific support services for DHS R&D activities in Washington, D.C., open to all eligible vendors.

Agency

Department of Homeland Security → DHS Hq/s&tView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Washington, DC, US

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedJan 1

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment of Homeland Security → DHS Hq/s&t

Contacts2 people available

OfficeN/A

Organization / Agency

Department of Homeland Security → DHS Hq/s&t

View Agency Profile

Office AddressN/A

Contacts

Cora Newton

contact@example.gov

+1 (555) 000-0000

Geoff SeaySmall Business Specialist/APFS Coordinator

contact@example.gov

+1 (555) 000-0000

Full Description

Show more

The objective of this requirement is to acquire professional scientific and technical support services with sufficient scientific background and operational expertise to effectively support a full range of operations and programmatic initiatives, inclusive of research, development, test and evaluation.

Similar Contracts

Same NAICS industry code

Onsite Installation and Commissioning Services for EPR System

UNIVERSITY of SOUTHERN MISSISSIPPI

POSTED

about 7 hours ago

DEADLINE

Extended Warranty Services for SwitchgearThe contract seeks to secure extended warranty services for air-insulated and solid dielectric pad-mounted switches, covering parts, labor, and technical support to ensure continued operational reliability. The scope is focused on maintaining system integrity through comprehensive post-sale service, addressing potential failures and performance issues over an extended period beyond standard manufacturer warranties. This effort is intended to minimize downtime and reduce long-term maintenance costs for critical electrical infrastructure used by the contracting entity. The solicitation is structured as a subcontract under NAICS code 541714, indicating it relates to scientific and technical consulting services. Posted on August 9, 2026, responses are due by September 10, 2026, at 4:30 PM. The contracting agency is Fayetteville State University in North Carolina, with no specific place of performance details provided. The procurement is not subject to a set-aside and is accessible via the official state procurement portal, though no point of contact information is listed within the available data.

Fayetteville State University

POSTED

DEADLINE

in about 1 month

Protein ENGineering (PENG)

Solicitation # DARPA-PS-26-129

The Defense Advanced Research Projects Agency (DARPA) is seeking innovative proposals under the Protein ENGineering (PENG) program, solicited through DARPA-PS-26-129, to develop a universal, software-defined platform for precise, programmable editing of endogenous proteins. The goal is to transform proteome engineering from fragmented, target-specific tools into an integrated system capable of directly recognizing, modifying, and rewriting proteins within complex biological environments using modular targeting, generalizable effector chemistries, and multiplexed control systems. Performers are expected to leverage novel splicing, ligation, and co-translational techniques to achieve these modifications in high-fidelity cellular models such as organoids, with progression from foundational validation to robust tissue-level demonstrations. The program is structured over a 42-month total period of performance, divided into an 18-month Base Phase 1, a 6-month Option Phase 1 for capability demonstration, and an 18-month Option Phase 2, spanning fiscal years 2027 through 2030. Performance will occur primarily at the contractor’s facility, with critical milestones requiring on-site demonstrations and DARPA team visits in Arlington, Virginia, where final evaluation and acceptance will take place. Proposals must adhere to strict formatting and documentation standards, including structured cost submissions using designated worksheets with sequentially numbered Reference Document IDs (e.g., EQ001, MAT010) for all equipment and materials over $5,000, supported by vendor quotes and detailed justifications. All cost estimates must comply with Federal Acquisition Regulation cost principles, and no deletion of template columns or cells is permitted. Key personnel—regardless of salary support—must be explicitly listed, and option periods must maintain continuity in document numbering with the base phase. While no explicit contract clauses, evaluation factors, or award methodology are provided, the solicitation emphasizes transparency, traceability, and compliance with Controlled Unclassified Information handling standards. Contractors must be prepared to submit proposals electronically by the October 19, 2026 deadline, with funding ceilings of up to $225,000 for Phase 1, $225,000 for Phase 2, and $160,000 for potential institutional innovation program participation, resulting in a maximum potential contract value of $610,000. No small business set-asides, socioeconomic certifications, or specific invoicing or payment office details are specified,

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)

Solicitation # W911SR-26-R-HEAL

The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.

POSTED

DEADLINE

Universal Cell Culture Platform for Rapid Establishment of Species-Agnostic Cell Lines and Autonomous Culture Operations

Solicitation # DPA26BZ05-DV020

Establishing cell culture systems for non-model vertebrate and invertebrate species remains a major bottleneck in biotechnology, severely limiting progress in gene-drive research, biocontrol development, and species-specific biomanufacturing. Current methods require years of labor-intensive, operator-dependent optimization tailored to each species, with protocols that rarely transfer between labs and lack reproducibility. This contract seeks an integrated platform that eliminates these inefficiencies by enabling rapid, universal derivation of stable cell lines from any species—regardless of taxonomic distance from established models—through species-agnostic biological techniques. These methods must support primary cell isolation, induced pluripotent stem cell reprogramming, and long-term maintenance using broadly applicable media, substrates, and reprogramming strategies that do not rely on species-specific reagents or markers, while also enabling validation of pluripotency, genomic stability, and differentiation potential in the absence of conventional reference tools. To accelerate this process, the platform must pair these biological innovations with fully autonomous, closed-loop automation capable of conducting high-throughput, parallelized experiments with minimal human intervention. The system must independently control environmental parameters at the vessel or well level, perform routine and complex cell culture operations—including feeding, passaging, imaging, and sampling—and use integrated machine-learning-driven analysis to interpret cellular health and morphology, then iteratively propose and execute new experimental conditions. This automation must generate fully digitized, transferable protocols that are reproducible across instruments and locations, compressing years of development into weeks or months. Where applicable, the platform must further support gene-drive and genetic-biocontrol research by providing validated cellular testbeds—including germline or developmentally relevant cell types—that enable in vitro measurement of homing efficiency, off-target activity, stability, and fitness costs, along with molecular containment and safety evaluation strategies. All work under the gene-drive component must remain strictly in vitro, with no environmental release or creation of gene-drive-competent organisms permitted, and must incorporate responsible research practices, biosafety protocols, and institutional oversight. The ultimate goal is a unified system that seamlessly links universal cell culture methods with automated optimization and targeted genetic validation to rapidly enable biological capabilities across the full spectrum of understudied species.

Defense Advanced Research Projects Agency

POSTED

DEADLINE

Evaluation of a Lead NNMT Inhibitor in Humanized M

Solicitation # 75N98026Q00941

The National Institutes of Health, Office of the Director, intends to award a non-competitive, firm-fixed price contract to GemPharmatech LLC for the evaluation of a lead NNMT inhibitor using a humanized nicotinamide N-methyltransferase mouse model, a model uniquely developed and maintained by GemPharmatech under prior NIH funding. This acquisition is conducted under streamlined commercial item procedures and is not expected to exceed the simplified acquisition threshold, with authority derived from FAR 12.603 and 41 U.S.C. 1901, and justified under the sole source exception for unique capabilities, as GemPharmatech is the only entity with the cryopreserved sperm and breeding resources necessary to regenerate the required mouse colony essential for generating scientifically relevant efficacy data due to the inhibitor's species-specific activity. The solicitation number is 75N98026Q00941, issued as a combined synopsis and solicitation without competitive procedures, and responses are due by August 19, 2026. The work falls under NAICS code 541714 for Research and Development in Biotechnology with a small business size standard of 1,000 employees, and this requirement is not set aside for small business. The contract will be managed by the NIH Office of Acquisitions based in Bethesda, Maryland, with the primary point of contact being Johnstona C. Johnston, reachable via email. All provisions and clauses follow those in effect through the Federal Acquisition Circular dated August 4, 2026, and the notice serves as the complete and only solicitation document; no additional written solicitation will be issued. The performance location is not specified beyond the federal agency's administrative details.

National Institutes Of Health Olao

POSTED

DEADLINE

Yeast Two-Hybrid (Y2H) Screening Service

Solicitation # 1232SA26Q1181

The U.S. Department of Agriculture’s Agricultural Research Service is soliciting quotations for Yeast Two-Hybrid (Y2H) Screening Services under solicitation number 1232SA26Q1181, issued as a combined synopsis and solicitation in accordance with FAR Part 12 for commercial items. This acquisition is exclusively reserved for small business concerns, with the North American Industry Classification System code 541714 for Research and Development in Biotechnology and a size standard of 1,000 employees, making it a total small business set-aside. Only responsible small business sources may submit quotations, which will be evaluated without the issuance of a separate written solicitation. The quote submission deadline is August 28, 2026, at 22:00 Eastern Time, with the solicitation publicly posted on August 4, 2026, and responses due to the USDA ARS office located in Beltsville, Maryland. The performance of the Y2H screening services is required to take place in Ithaca, New York, 14853. The primary point of contact for inquiries is Kerrie Hodges, reachable via email at kerrie.hodges@usda.gov. The contract is being procured by the USDA ARS Affiliated Programs and Development office and is intended to support research activities for the Robert W. Holley Center for Agriculture and Health. Interested parties must submit their quotations through the SAM.gov platform using the provided UI link, and all responses must comply with the commercial item procurement procedures outlined in FAR Part 12. No further documentation or separate solicitation documents will be issued.

USDA Ars Afm Apd

POSTED

DEADLINE

Solicitation # 1232SA26Q0963

This solicitation, numbered 1232SA26Q0963, is a combined synopsis and request for quotation for genotyping services under FAR Part 12, with no separate written solicitation to follow. It is a total small business set-aside, restricted exclusively to small businesses as defined by the NAICS code 541714 and the 1,000-employee size standard. All responsible small business sources are encouraged to submit quotations, which will be evaluated based on criteria outlined in Attachment 1, which includes the full terms, conditions, and evaluation parameters. The solicitation incorporates provisions and clauses by reference, accessible electronically at www.acquisition.gov. The contract is issued by the USDA ARS AFM APD, with the office located in Beltsville, Maryland, and performance required in Maricopa, Arizona, ZIP 85138. Responses are due by August 12, 2026, at 7:00 p.m. Eastern Time, and the opportunity was posted on August 4, 2026. The primary point of contact for inquiries is Frank Palmer, reachable via email at frank.palmer@usda.gov, and additional details can be viewed on the SAM.gov website at the provided UI link.

USDA Ars Afm Apd

POSTED

DEADLINE

Emerging Infections Network - Research for Preventing, Detecting, and Managing Travel-associated Infectious Diseases

Solicitation # RFA-CK-26-035

The Centers for Disease Control and Prevention, under the Department of Health and Human Services, is soliciting applications through RFA-CK-26-035 to establish a dual-component surveillance network aimed at detecting, preventing, and managing infectious diseases among international travelers. The initiative targets two key environments: clinic-based sentinel sites serving travelers and wastewater-based monitoring at major international transportation hubs, including airports in Addis Ababa, Nairobi, Istanbul, Bangkok, Seoul, and São Paulo. The goal is to enhance early outbreak detection, refine diagnostic and treatment strategies, improve genomic surveillance, and strengthen global health security by generating timely, actionable public health data. Applications may be submitted for Component A, Component B, or both, with the understanding that if a proposal for both components is top-ranked, only Component B will be funded. The program is structured as a cooperative agreement with a five-year performance period beginning September 1, 2027, and an estimated total funding range of $8.75 million to $30 million across both components, with annual funding tiers specified per component. Applicants must adhere to strict submission protocols using the NIH SF-424 (R&R) application package, including a 12-page research strategy per component and a 1-page specific aims section, with no more than 10 PDF attachments allowed in the appendix. Critical requirements include registration in SAM.gov for a Unique Entity ID, eRA Commons registration for all key personnel, IRB approval for human subjects research, OMB-PRA clearance for data collection, and submission of a Bona Fide Agent document, an indirect cost agreement, and a report on proposal overlap if applicable. The CDC will maintain substantial programmatic involvement, requiring prior approval for publications and active collaboration in project execution. Evaluation is based on five scientific merit criteria—Significance, Investigators, Innovation, Approach, and Environment—scored on a 1-to-9 scale, with the final award decision guided by scientific merit, program relevance, portfolio balance, and geographic distribution, not cost. Payment is administered under federal grant rules, with indirect costs capped at 15% using the de minimis rate unless an approved rate is provided. Final reports are due 120 days after project completion, and all data must be shared via the global GLOWACON platform under standardized protocols for wastewater sampling, metagenomic sequencing, and bioinformatics analysis.

Centers For Disease Control And Prevention

POSTED

DEADLINE

Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_PreSolNotice_NPIVS-2027

The U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), is seeking qualified contractors to support the ongoing Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. Contractors must be capable of furnishing all necessary services, personnel, equipment, materials, and U.S.-based facilities to produce vaccines, antigens, and adjuvants for pandemic influenza and other viruses with pandemic potential. To be eligible, offerors must either hold an active U.S. influenza vaccine license from the FDA or have submitted a Biologics License Application for a seasonal or pandemic influenza vaccine. The program demands the generation and submission of comprehensive regulatory data—including analytical, nonclinical, clinical, and chemistry, manufacturing, and controls (CMC) information—to the FDA to enable rapid decision-making and maintain manufacturing readiness during interpandemic periods. The anticipated contract is an indefinite delivery, indefinite quantity (IDIQ) vehicle with a base performance period of 60 months and the potential to extend up to 120 months if all option periods are exercised, combining both cost-reimbursement and firm-fixed-price task orders. Performance is expected to occur primarily within the United States, with the place of performance designated as Washington, D.C., and the contracting office located at 400 7th Street SW. Proposals must be submitted electronically via SAM.gov by the deadline of August 15, 2026, and are subject to evaluation based on mandatory qualification requirements, with full evaluation factors and source selection criteria expected to be detailed in the forthcoming Request for Proposals. The solicitation number is 75A50126R00001, and the NAICS code is 541714 for research and development in biotechnology. The primary point of contact for inquiries is Laura Saddison, BARDA Contracting Officer, reachable at Laura.Saddison@hhs.gov. No set-aside is planned, and full and open competition is anticipated. While packaging, marking, inspection procedures, and specific invoicing methods are not defined in this presolicitation, contractors should prepare to comply with FDA regulatory standards and anticipate the use of federal systems such as WAWF for payment processing. No contracting officer’s representative or technical representative has been designated yet, and all certifications and representations will be required upon formal proposal submission.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Convergence Special Notice

Solicitation # DARPA-SN-26-108

The Convergence program seeks to revolutionize environmental monitoring for defense operations by integrating synthetic biology and engineering to create advanced microbial biosensors capable of detecting chemical and pharmaceutical hazards in austere environments. Leveraging non-pathogenic microbial consortia built on well-characterized, safe host organisms like E. coli, the initiative focuses on developing modular biological systems that translate environmental inputs into standardized, detectable outputs. The program’s development follows a structured four-tiered approach, progressing from component-level design and integrated payload engineering to full system integration within a microbial chassis, ultimately aiming for a deployable platform ready for U.S. and international regulatory certification. This systematic progression ensures that each layer of functionality is rigorously validated before scaling to operational readiness. To enable safe, responsible, and globally viable deployment, the program includes a dedicated ecosystem of testing and collaboration. Performance and safety validation will first occur within the United States before exploring international adoption, with two specialized working groups guiding the process: one focused on navigating socio-political landscapes and local environmental regulations, and another managing cooperative use cases and deployment protocols with global allies. Administered by DARPA, the solicitation under number DARPA-SN-26-108 invites multidisciplinary teams in synthetic biology, environmental science, and engineering to contribute to this initiative, with responses due by August 6, 2026. The program is headquartered in Arlington, Virginia, and is led by Mark Salvador, with the goal of delivering a scalable, secure, and globally interoperable biosensor platform for the protection of military personnel.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Multiscale Reasoning For Human Physiology RFI

Solicitation # DARPA-SN-26-100

The Defense Advanced Research Projects Agency’s Biological Technologies Office is seeking input on cutting-edge technologies that enable multiscale reasoning across human physiology through this Request for Information, identified as DARPA-SN-26-100. The focus is on emerging tools including artificial intelligence systems, foundation models, computational frameworks, and datasets capable of integrating biological, physiological, and clinical data across multiple scales—from molecular and cellular levels to organ systems and whole-body responses. The goal is to advance the ability to model, predict, and interpret complex human physiological behavior using AI and data-driven approaches, with interest in non-traditional performers and innovative solutions from industry, academia, government labs, and healthcare organizations. Responses are due by August 10, 2026, and the solicitation falls under NAICS code 541714 for research and development in the physical, engineering, and life sciences. All submissions should be directed to Dr. Roozbeh Jafari, Program Manager at DARPA/BTO, via bioreasoning@darpa.mil. The office is located in Arlington, Virginia, and while no specific place of performance is defined, selected technologies may be developed and evaluated through future DARPA programs. This RFI does not constitute a solicitation for proposals or obligations but aims to inform upcoming funding opportunities in the field of physiological modeling and AI-driven biological insight.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE